Alliance E-News | December 2024
Scientific Annual Meetings
The American Society of Hematology (ASH) works to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training and advocacy in hematology. The society's scientific meetings facilitate the exchange of scientific information and clinical results related to the field of hematology.
Alliance presented six abstracts at this year's symposium held on December 7-10, 2024 in San Diego, CA.
224 Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated With Favorable Outcomes In Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial (Alliance)
Lead Authors: Meagan A. Jacoby, David H. Spencer
Oral Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond
218 10 Year Follow-up of CALGB 10603/RATIFY: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
Lead Author: Richard Stone
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML
Session Presentation
308 The Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Adult Patients with B-cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Trial
Lead Author: Daniel J. DeAngelo
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients
4502.4 Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma (PCNSL)
Lead Author: Alvaro J. Alencar
Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III
1661.3 Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Lead Author: Anne W. Beaven
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
110 Representation of Minorities in Therapeutic Clinical Trials – A 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
Lead Author: Alvaro J. Alencar
Oral Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies
